Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer

Burg, M. E. van der; Vergote, Ignace; Burger, C.W.; Gaast, Ate van der

doi:10.1200/jco.2004.22.90140.5058

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been combined with weekly platinum. In one study 16 of weekly induction therapy with carboplatin AUC 4 and paclitaxel 90 mg/m 2 , there was a response in 53% of women with a platinum‐free interval (PFI) <6 months and in 80% of those with a PFI >6 months. Grade 3 or 4 neutropenia occurred in 31%, but fever in only 1.7% of cases.…”

Section: Dose‐dense Chemotherapymentioning

confidence: 99%

Current practice and new developments in ovarian cancer chemotherapy

Ali

Ledermann²

2007

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content A combination of carboplatin and paclitaxel is the most commonly used treatment for advanced ovarian cancer, a chemosensitive disease with a high recurrence rate. Molecular targeted agents are being investigated as a novel strategy to improve the outcome of systemic therapy. Learning objectives To study the optimum timing of chemotherapy in relation to surgery and the role of intraperitoneal therapy. To be aware of current chemotherapy regimens used in the management of newly diagnosed and relapsed ovarian cancer and the rationale for using them. To understand current areas of research using novel agents in systemic therapy and different treatment strategies. Ethical issues It is important to consider the balance between benefit and side effects of treatment for women with relapsed disease. Patient choice is an important consideration for the selection of chemotherapy for relapsed ovarian cancer. Current treatment produces only a modest gain in outcome, therefore, every effort should be made to recruit women to clinical trials. Please cite this article as: Ali SN, Ledermann JA. Current practice and new developments in ovarian cancer chemotherapy. The Obstetrician & Gynaecologist 2007;9:265–269.

show abstract

Section: Dose‐dense Chemotherapymentioning

confidence: 99%

Current practice and new developments in ovarian cancer chemotherapy

Ali

Ledermann²

2007

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

show abstract

“…This produced an overall 83% response rate (24/29 patients), which included a 37.5% response rate in 8 platinum‐refractory patients and a 100% response rate for patients with platinum‐sensitive disease. Another similar schedule using higher doses of carboplatin area under the curve 4 plus paclitaxel 90 mg/m 2 given weekly for six cycles (with a 2‐week break between cycles 3 and 4) produced a 53% response rate in 18 of 50 enrolled platinum‐resistant patients who had a PFI of <6 months (38) . However, this regimen was used as a form of “induction” therapy as responding patients were then treated by six conventional 3‐weekly cycles of carboplatin–paclitaxel.…”

Section: Background and Definitionsmentioning

confidence: 99%

"Dose dense" chemotherapy in ovarian cancer

Vasey

2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

In essence, dose densification is "accelerated therapy" (a commonly used phrase in radiotherapeutics) and is a form of dose intensification because the amount of drug per unit time (dose intensity = mg/m(2)/week) is increased. There is general consensus that increasing platinum dose intensity in ovarian carcinoma has not been proven despite a dozen or more randomized trials evaluating up to twofold increases in dose intensity. Few randomized trials in ovarian carcinoma have compared weekly "dose dense" chemotherapy with more conventional dosing schedules although there are plenty of phase II studies. In these, dose densification of single agent therapy, for some drugs at least, appears to be relatively well tolerated, with encouraging levels of activity in patients purportedly refractory to the same agents when scheduled in the standard way. However, many studies ostensibly evaluating "dose density" do not actually evaluate this entity, but actually split the standard 3-weekly dose into weekly fragments thus maintaining the same dose intensity. Furthermore, as the aim of treatment in recurrent ovarian cancer is palliation, weekly treatments are less convenient, are probably less cost effective, and have different dose-limiting toxicities. This article will review the clinical data supporting dose density as a therapeutic maneuver in ovarian cancer.

show abstract

“…This produced an overall 83% response rate (24/29 patients), which included a 37.5% response rate in 8 platinum-refractory patients and a 100% response rate for patients with platinum-sensitive disease. Another similar schedule using higher doses of carboplatin area under the curve 4 plus paclitaxel 90 mg/m 2 given weekly for six cycles (with a 2-week break between cycles 3 and 4) produced a 53% response rate in 18 of 50 enrolled platinum-resistant patients who had a PFI of ,6 months (38) . However, this regimen was used as a form of ''induction'' therapy as responding patients were then treated by six conventional 3-weekly cycles of carboplatin-paclitaxel.…”

Section: Combinations In Dose Dense Schedules?mentioning

confidence: 99%

“Dose dense” chemotherapy in ovarian cancer

VASEY

2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

In essence, dose densification is “accelerated therapy” (a commonly used phrase in radiotherapeutics) and is a form of dose intensification because the amount of drug per unit time (dose intensity = mg/m2/week) is increased. There is general consensus that increasing platinum dose intensity in ovarian carcinoma has not been proven despite a dozen or more randomized trials evaluating up to twofold increases in dose intensity. Few randomized trials in ovarian carcinoma have compared weekly “dose dense” chemotherapy with more conventional dosing schedules although there are plenty of phase II studies. In these, dose densification of single agent therapy, for some drugs at least, appears to be relatively well tolerated, with encouraging levels of activity in patients purportedly refractory to the same agents when scheduled in the standard way. However, many studies ostensibly evaluating “dose density” do not actually evaluate this entity, but actually split the standard 3-weekly dose into weekly fragments thus maintaining the same dose intensity. Furthermore, as the aim of treatment in recurrent ovarian cancer is palliation, weekly treatments are less convenient, are probably less cost effective, and have different dose-limiting toxicities. This article will review the clinical data supporting dose density as a therapeutic maneuver in ovarian cancer.

show abstract

Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer

Cited by 6 publications

References 0 publications

Current practice and new developments in ovarian cancer chemotherapy

Current practice and new developments in ovarian cancer chemotherapy

"Dose dense" chemotherapy in ovarian cancer

“Dose dense” chemotherapy in ovarian cancer

Contact Info

Product

Resources

About